The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression - PubMed (original) (raw)

The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression

Astrid Bjørnebekk et al. Hippocampus. 2010 Jul.

Abstract

One hypothesis of depression is that it is caused by reduced neuronal plasticity including hippocampal neurogenesis. In this study, we compared the effects of three long-term antidepressant treatments: escitalopram, voluntary running, and their combination on hippocampal cell proliferation, NPY and the NPY-Y1 receptor mRNAs, targets assumed to be important for hippocampal plasticity and mood disorders. An animal model of depression, the Flinders Sensitive Line (FSL) rat, was used and female rats were chosen because the majority of the depressed population is females. We investigated if these treatments were correlated to immobility, swimming, and climbing behaviors, which are associated with an overall, serotonergic-like and noradrenergic-like antidepressant response, in the Porsolt swim test (PST). Interestingly, while escitalopram, running and their combination increased the number of hippocampal BrdU immunoreactive cells, the antidepressant-like effect was only detected in the running group and the group with access both to running wheel and escitalopram. Hippocampal NPY mRNA and the NPY-Y1 receptor mRNA were elevated by running and the combined treatment. Moreover, correlations were detected between NPY mRNA levels and climbing and cell proliferation and NPY-Y1 receptor mRNA levels and swimming. Our results suggest that increased cell proliferation is not necessarily associated with an antidepressant effect. However, treatments that were associated with an antidepressant-like effect did regulate hippocampal levels of mRNAs encoding NPY and/or the NPY-Y1 receptor and support the notion that NPY can stimulate cell proliferation and induce an antidepressant-like response.

PubMed Disclaimer

Cited by

Exercise for Mental Well-Being: Exploring Neurobiological Advances and Intervention Effects in Depression.
Ren J, Xiao H. Ren J, et al. Life (Basel). 2023 Jul 4;13(7):1505. doi: 10.3390/life13071505. Life (Basel). 2023. PMID: 37511879 Free PMC article. Review.
Protective Role and Functional Engineering of Neuropeptides in Depression and Anxiety: An Overview.
Okdeh N, Mahfouz G, Harb J, Sabatier JM, Roufayel R, Gazo Hanna E, Kovacic H, Fajloun Z. Okdeh N, et al. Bioengineering (Basel). 2023 Feb 16;10(2):258. doi: 10.3390/bioengineering10020258. Bioengineering (Basel). 2023. PMID: 36829752 Free PMC article. Review.
Intranasal Neuropeptide Y as a Potential Therapeutic for Depressive Behavior in the Rodent Single Prolonged Stress Model in Females.
Nahvi RJ, Tanelian A, Nwokafor C, Hollander CM, Peacock L, Sabban EL. Nahvi RJ, et al. Front Behav Neurosci. 2021 Sep 8;15:705579. doi: 10.3389/fnbeh.2021.705579. eCollection 2021. Front Behav Neurosci. 2021. PMID: 34566592 Free PMC article.
Chronic Escitalopram Treatment Does Not Alter the Effects of Neonatal Stress on Hippocampal BDNF Levels, 5-HT1A Expression and Emotional Behaviour of Male and Female Adolescent Rats.
Henn L, Zanta NC, Girardi CEN, Suchecki D. Henn L, et al. Mol Neurobiol. 2021 Mar;58(3):926-943. doi: 10.1007/s12035-020-02164-1. Epub 2020 Oct 15. Mol Neurobiol. 2021. PMID: 33063280
Sex Differences in the Neuropeptide Y System and Implications for Stress Related Disorders.
Nahvi RJ, Sabban EL. Nahvi RJ, et al. Biomolecules. 2020 Aug 27;10(9):1248. doi: 10.3390/biom10091248. Biomolecules. 2020. PMID: 32867327 Free PMC article. Review.

The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression - PubMed (original) (raw)